Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy
29 mars 2019 09h00 HE
|
Genprex, Inc.
NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – GNPX)">Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Advanced Medical...
Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Innovative Cancer Treatments
28 mars 2019 08h30 HE
|
Genprex, Inc.
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — GNPX)">Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted...
NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability
14 mars 2019 08h30 HE
|
NetworkNewsWire
NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial...
Biodesix Test Predicts Response to Atezolizumab in Lung Cancer
12 nov. 2018 09h00 HE
|
Biodesix, Inc.
Researchers Present New Data from Blood-Based Proteomic Test in Biomarkers and Immune Monitoring at SITC 2018 BOULDER, Colo. and WASHINGTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Researchers with...
Biodesix Presents Positive Data in Detection of Primary Immunotherapy Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer
22 oct. 2018 03h00 HE
|
Biodesix, Inc.
Serum Proteomic Test Could Optimize Treatment by Identifying Patients Unlikely to Benefit from Immunotherapy BOULDER, Colo. and MUNICH, Germany, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Biodesix®...
Biodesix Pipeline Test Demonstrates Utility in Triaging Patients with Lung Nodules in New CHEST Data Publication
10 sept. 2018 08h18 HE
|
Biodesix, Inc.
BOULDER, Colo., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Biodesix today announced newly published data showing the noninvasive BDX-XL2 test, currently in development, could reduce the number of...
Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
29 août 2018 08h21 HE
|
Biodesix, Inc.
BOULDER, Colo., Aug. 29, 2018 (GLOBE NEWSWIRE) -- A new study published in The Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell...
Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other
11 sept. 2017 07h57 HE
|
Visiongain Ltd
LONDON, Sept. 11, 2017 (GLOBE NEWSWIRE) -- The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the...
New Data Show Biodesix’s VeriStrat® Test is Cost-Saving, Improves Survival and Quality of Life in Advanced Lung-Cancer Patients
03 avr. 2017 13h08 HE
|
Biodesix, Inc.
BOULDER, Colo., April 03, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today new data demonstrating that use of the VeriStrat® test in patients with advanced non-small cell lung cancer (NSCLC)...
Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 Congress
10 oct. 2016 08h05 HE
|
Peregrine Pharmaceuticals Inc.
-- Company Has Identified Beta-2 Glycoprotein-1 (β2GP1) as a Biomarker that Correlates with Statistically Significant Improvement in Overall Survival for Patients Receiving the Bavituximab...